FTIDC - CAS 873551-53-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H23FN6O
Molecular Weight:
358.41
COA:
Inquire
Targets:
mGluR
Description:
FTIDC is an orally bioactive mGlu1 receptor negative allosteric modulator (IC50 = 5.8 and 6200 nM for mGlu1 and mGlu5, respectively) and an mGlu1 receptor inverse agonist (IC50 = 7 nM) in the absence of ligand. FTIDC exhibits anxiolytic and antipsychotic effects in vivo.
Brife Description:
mGlu1 receptor antagonist
Purity:
≥98% by HPLC
Synonyms:
4-[1-(2-Fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-3,6-dihydro-N-methyl-N-(1-methylethyl)-1(2H)-pyridinecarboxamide
MSDS:
Inquire
InChIKey:
CJTLKLBSIFQKNT-UHFFFAOYSA-N
InChI:
InChI=1S/C18H23FN6O/c1-12(2)23(4)18(26)24-10-7-14(8-11-24)16-13(3)25(22-21-16)15-6-5-9-20-17(15)19/h5-7,9,12H,8,10-11H2,1-4H3
Canonical SMILES:
CC1=C(N=NN1C2=C(N=CC=C2)F)C3=CCN(CC3)C(=O)N(C)C(C)C
1.Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Suzuki G;Kimura T;Satow A;Kaneko N;Fukuda J;Hikichi H;Sakai N;Maehara S;Kawagoe-Takaki H;Hata M;Azuma T;Ito S;Kawamoto H;Ohta H J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.
A highly potent and selective metabotropic glutamate receptor (mGluR) 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2, 3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC), is described. FTIDC inhibits, with equal potency, l-glutamate-induced intracellular Ca(2+) mobilization in Chinese hamster ovary cells expressing human, rat, or mouse mGluR1a. The IC(50) value of FTIDC is 5.8 nM for human mGluR1a and 6200 nM for human mGluR5. The maximal response in agonist concentration-response curves was reduced in the presence of higher concentrations of FTIDC, suggesting the inhibition in a noncompetitive manner. FTIDC at 10 microM showed no agonistic, antagonistic, or positive allosteric modulatory activity toward mGluR2, mGluR4, mGluR6, mGluR7, or mGluR8. FTIDC did not displace [(3)H]l-quisqualate binding to human mGluR1a, indicating FTIDC is an allosteric antagonist. Studies using chimeric and mutant receptors of mGluR1 showed that transmembrane (TM) domains 4 to 7, especially Phe801 in TM6 and Thr815 in TM7, play pivotal roles in the antagonism of FTIDC. FTIDC inhibited the constitutive activity of mGluR1a, suggesting that FTIDC acts as an inverse agonist of mGluR1a.
2.Face-washing behavior induced by the group I metabotropic glutamate receptor agonist (S)-3,5-DHPG in mice is mediated by mGlu1 receptor.
Hikichi H;Iwahori Y;Murai T;Maehara S;Satow A;Ohta H Eur J Pharmacol. 2008 May 31;586(1-3):212-6. doi: 10.1016/j.ejphar.2008.02.061. Epub 2008 Feb 29.
It is known for the non-selective group I metabotropic glutamate (mGlu) receptors agonist (S)-3,5-dihydroxyphenylglycine (S-3,5-DHPG) to cause convulsions, which are mediated by mGlu1 receptor. However, the behavioral changes other than convulsions caused by (S)-3,5-DHPG have not been well studied. The purpose of the present study was to explore the behavioral changes elicited by activation of group I mGlu receptors with (S)-3,5-DHPG and to clarify which, mGlu1 receptor or mGlu5 receptor, is responsible for such behavior. (S)-3,5-DHPG at doses of 3-30 nmol caused characteristic face-washing behavior. This behavioral change was inhibited by both the competitive mGlu1 receptor antagonists (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA) and (S)-4-carboxyphenylglycine (S-4CPG) and the non-competitive mGlu1 receptor antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC), but not by the mGlu5 receptor antagonist 2-Methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP), the mGlu2/3 receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), the mGlu2/3 receptor antagonist (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), the N-methyl-d-asparate (NMDA) receptor antagonist 5R,10S-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801), or the competitive non-NMDA receptor antagonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX).
3.Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists.
Suzuki G;Kawagoe-Takaki H;Inoue T;Kimura T;Hikichi H;Murai T;Satow A;Hata M;Maehara S;Ito S;Kawamoto H;Ozaki S;Ohta H J Pharmacol Sci. 2009 Jul;110(3):315-25. Epub 2009 Jun 19.
The aim of this study was to clarify the relationship between receptor occupancy and in vivo pharmacological activity of mGluR1 antagonists. The tritiated mGluR1-selective allosteric antagonist [(3)H]FTIDC (4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide) was identified as a radioligand having high affinity for mGluR1-expressing CHO cells (K(D) = 2.1 nM) and mouse cerebellum (K(D) = 3.7 nM). [(3)H]FTIDC bound to mGluR1 was displaced by structurally unrelated allosteric antagonists, suggesting there is a mutual binding pocket shared with different allosteric antagonists. The binding specificity of [(3)H]FTIDC for mGluR1 in brain sections was demonstrated by the lack of significant binding to brain sections prepared from mGluR1-knockout mice. Ex vivo receptor occupancy with [(3)H]FTIDC revealed that the receptor occupancy level by FTIDC correlated well with FTIDC dosage and plasma concentration. Intracerebroventricular administration of (S)-3,5-dihydroxyphenylglycine is known to elicit face washing behavior that is mainly mediated by mGluR1. Inhibition of this behavioral change by FTIDC correlated with the receptor occupancy level of mGluR1 in the brain.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products


CAS 1309976-62-2 VU 0360172 hydrochloride

VU 0360172 hydrochloride
(CAS: 1309976-62-2)

VU 0360172 hydrochloride is a positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM) with potential antipsychotic-like activity. VU 036017...

CAS 873551-53-2 FTIDC

FTIDC
(CAS: 873551-53-2)

FTIDC is an orally bioactive mGlu1 receptor negative allosteric modulator (IC50 = 5.8 and 6200 nM for mGlu1 and mGlu5, respectively) and an mGlu1 receptor inver...

CAS 409345-29-5 JNJ 16259685

JNJ 16259685
(CAS: 409345-29-5)

JNJ 16259685, a pyrano-quinolin derivative, has been found to be a metabotropic glutamate receptor-1 antagonist.

ML337
(CAS: 1443118-44-2)

ML337 is a Selective negative allosteric modulator of mGlu3 with IC50 value of 593 nM. It shows no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 3...

FITM
(CAS: 932737-65-0)

FITM is a potent mGlu1 inhibitor (Ki = 2.5 nM) with great selectivity that does not disrupt mGlu5.

CAS 246852-46-0 Ro 64-5229

Ro 64-5229
(CAS: 246852-46-0)

Ro 64-5229 is a selective, non-competitive mGlu2 antagonist.

CAS 1623101-11-0 VU-0483605

VU-0483605
(CAS: 1623101-11-0)

VU-0483605, an isoindol derivative, has been found to be a mGluR1 positive allosteric modulator and probably be effective against schizophrenia. EC50: 356 and 3...

CAS 407-41-0 O-Phospho-L-serine

O-Phospho-L-serine
(CAS: 407-41-0)

O-Phospho-L-serine, a molecule which resembles phosphatidylserine head group, is an agonist of the group III metabotropic glutamate receptors mGluR4a and mGluR6...

Chemical Structure

CAS 873551-53-2 FTIDC

Quick Inquiry

Verification code

Featured Items